



The Fast Track to Best-in-Class Cell Lines

Selexis® TranspoEase™

99%

stable cell lines
across 60 generations

Up to 18 g/L

titers for mAbs
with KBI's feed

9 Weeks

from transfection
to RCB

KBI Biopharma's cell line development – powered by Selexis® TranspoEase™ – delivers an elite, category-setting transposase-based technology that is built on the SUREtechnology Platform™.

The process leverages semi-targeted integration and bi-select process, delivering 99% cell line stability and 18 g/L titer within 9 weeks “for mAbs”. Validated by 14 marketed products and 30+ years of proven performance, you now have access to the best-in-class cell line development (CLD) technology.

14

Marketed Products

30+

Years of Experience

190+

Drug Candidates

Why TranspoEase Matters?



Your CLD partner is the foundation for your next 10-15 years of development. Why settle for outdated technology or unproven results?




With KBI, you get reliable, high-performing cell lines and a group of experts who understand your molecule's unique challenges.




Selexis® TranspoEase™ delivers consistent, high-titer expression need to meet critical milestones and advance with confidence with the speed your program deserves.

Stable: 99% Cell Line Stability



High Titer Across Diverse Molecules*



*not using KBI's proprietary feed


Speed: 9 Weeks to RCB

Vector Construction

Selection

Expansion Banking

Stability Study



1

2

3

4

5

6


7

Transfection


Clone Isolation

Lead Evaluation

Scalable: Built on the CHO-M Foundation



Track Record: Supports Various Formats



Ready to Build Your Foundation?

Contact the KBI Biopharma team to discuss how Selexis® TranspoEase™ can accelerate your program. **Fast, stable, productive, transposase-enabled CLD platform built on the proven Selexis® SUREtechnology Platform™.**

Science Driven. Customer Focused. Visit kbibiopharma.com to learn more.

